landingpage_aplomex.png

Computational Peptide Design

Developing Next-generation Therapeutics

 
 
About Us

Aplomex a computational start-up focused on the discovery, design, and development of novel constrained peptides as next-generation therapeutics for the treatment of chronic and  metabolic diseases.

Our founders are scientists from A*STAR, Singapore who have worked with academia, clinical and pharma partners over the past two decades.

Aplomex is interested to partner with pharmaceutical companies to apply its computational platform for development of peptide based drug molecules directed at  targets  of interest. 

We also provide state-of-the-art molecular modeling services to life science research institutions and start-ups, pharmaceutical or biotech companies.

 
team.png

Meet the Team

Aplomex founders are scientists from the Agency for Science, Technology and Research (A*STAR), based in Singapore, with several years of experience in novel drug discovery

Chandra_3_edited.jpg

Chandra Verma

Co-Founder

Ragav_edited.jpg

Srinivasaraghavan Kannan

Co-Founder

 
Drug modalities
Peptides: The Balanced Molecule
Untitled.jpg

peptide

Sketch Arrow Down

large

molecule

Sketch Arrow 2

small

molecule

Sketch Arrow 2

Peptides bridge the gap between small molecules and large molecules (biologics) with characteristics of high affinity, specificity,  cell permeability, biocompatibility, and lower toxicity.

However, their applicability as therapeutics is limited due to their poor chemical and physical stability, short half-life, and limited cell permeability.

aplomex2.jpg

Our Platform

Our proprietary in-silico peptide design platform (PepDeSim)  is a validated state-of-the-art computational platform for rapid discovery and development of novel constrained peptides.
 
Developed in the founder's lab at A*STAR, Singapore, "PepDeSim" can be applied to any target of interest ranging from extracellular to trans-membrane and intracellular proteins.
Aplomex utilizes its computational platform for the discovery of novel constrained peptide hit molecules and further development of those into preclinical candidates.

 

Our Strategy

3R Strategy

3D Strategy

3d3r.png

These highly specific constrained peptides are much smaller than biologics, enabling more convenient routes of administration. The nature of the constrained peptides (relatively smaller size, resistance to harsh conditions such as stomach acids/digestion and intestinal absorption) offers the possibility of oral administration. The constrained peptides have the potential to become next generation orally-available peptide drugs.

 
Constrained Peptides  - The Balanced Peptide Drug

Constrained peptides are a new class of molecules that combine the diversity and specificity of antibodies with the pharmacological properties of small, synthetic molecules. With its potentially improved tissue penetration and ability to modulate the undruggable protein-protein interactions (PPIs) constrained peptides expand the druggable world.

 
 

Service

We apply state-of-the-art computational methods to provide high quality, efficient and cost-effective molecular modeling services to assist in diverse aspects of your research and development.

Our Expertise

  • Molecular modeling and molecular dynamics simulation of biomolecules and their complexes  

  • Identification of potential orthosteric, allosteric  and novel cryptic pockets in biomolecules

  • Structure-based virtual screening to discover potential  hit molecules, and further optimization

  • Identification and characterization of protein-protein interactions (PPI).

  • In-silico docking for modeling protein-peptide complexes

  • Protein and peptide (peptidomimetics) design, engineering and optimization

Our Service Model

  • Customized project timelines (FTE and project-based).

  • IPs generated under the projects remain with the client.

  • Open to academic collaborations. 

  • Manage compound procurement including synthesis of small molecules, peptides, peptidomimetics, and in-vitro, cell-based, in-vivo assays (with Third Party Partners).

 
canvas.png

Contact Us

A*STARTCentral, #05-03,

79 Ayer Rajah Crescent​, Singapore 139955